The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Genzyme is voluntarily recalling nine lots of its kidney transplant drug Thymoglobulin after one product lot failed a periodic stability test, the Sanofi subsidiary says.
The additional lots of the antibody were pulled because they were made with raw materials of comparable quality to the lot that was flagged, Genzyme explained. Those materials, determined to be the root cause of the stability failure, could potentially weaken the drug before it expires, the drugmaker noted. Drug Industry Daily